Advertisement

How to Induce Arrhythmias with Isoprenaline

  • Sorin Pripon
Chapter

Abstract

Isoprenaline is an analog of epinephrine with a pure β1 and β2 effect. It is the isopropylamine of epinephrine and acts nonselectively on beta-receptors from the heart, bronchi, skeletal muscle, and alimentary tract. It is used for its bronchodilator and positive chronotropic effect. It was used in asthma, but at the moment there are other β2 selective agonists that are preferred. In the 1930s, isoprenaline was used as a vasoconstrictor and decongestant. Later it was injected during anesthesia because it could maintain the blood pressure without reduction of the perfusion into the vital organs.

References

  1. 1.
    Conolly ME, Davies DS, Dollery CT, George CF. Resistance to B-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Br J Pharmacol. 1971;43:389–402.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Choi EK, Kumar S, Nagashima K, Lin KY, Barbhaiya CR, Chinitz JS, et al. Better outcome of ablation for sustained outflow-tract ventricular tachycardia when tachycardia is inducible. Europace. 2015;17:1571–9.CrossRefGoogle Scholar
  3. 3.
    Oral H, Crawford T, Frederick M, Gadeela N, Wimmer A, Dey S, et al. Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:466–70.CrossRefGoogle Scholar
  4. 4.
    Min Park Y, Soo Lee H, Lim RA. Inadvertently developed ventricular fibrillation during Electrophysiologic study and catheter ablation: incidence, cause, and prognosis. Korean Circ J. 2013;43:474–80.CrossRefGoogle Scholar
  5. 5.
    Hertring G. The fate of 3H-iso-proterenol in the rat. Biochem Pharmacol. 1964;13:1119–28.CrossRefGoogle Scholar
  6. 6.
    Conolly ME, Davies DS, Dollery CT, Morgant CD, Patersons JW, Sandler M. Metabolism of isoprenaline in dog and man. Br J Pharmacol. 1972;46:458–72.CrossRefGoogle Scholar
  7. 7.
    Balazs T, Ohtake S, Cummings JR, Noble JF. Ventricular extrasystoles induced by epinephrine, nicotine, ethanol and vasopressin in dogs with myocardial lesions. Toxicol Appl Pharmacol. 1969;15:189.CrossRefGoogle Scholar
  8. 8.
    Osborne BE. Uses and applications of electrocardiography in toxicology. Proc Eur Soc Study Drug Toxic. 1974;15:85.Google Scholar
  9. 9.
    Gopinath C, Thuring J, Zayed I. Isoprenaline-induced myocardial necrosis in dogs. Br J Exp Pathol. 1978;59:148–57.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Markel ML, Mile WM, Luck JC, Klein LS, Prytowsky EN. Differential effect of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy. Circulation. 1993;87:783–92.CrossRefGoogle Scholar
  11. 11.
    Coelho A, Palileo E, Ashley W, Swiryn S, Petropoulos T, Welch WJ, et al. Tachyarrhythmias in young athletes. J Am Coll Cardiol. 1986;7:237–43.CrossRefGoogle Scholar
  12. 12.
    Brownstein SL, Hopson RC, Martins JB, Aschoff AM, Olhansky B, Constantin L, et al. Usefulness of isoproterenol in facilitating atrioventricular nodal reentry tachycardia during electrophysiological testing. Am J Cardiol. 1988;61:1037–41.CrossRefGoogle Scholar
  13. 13.
    Hariman RJ, Gomes JAC, El-Sherif N. Cathecolamine-dependent atrioventricular nodal reentrant tachycardia. Circulation. 1983;67:681–6.CrossRefGoogle Scholar
  14. 14.
    Brembilla-Perrot B, Terrier de la Chaise A, Pichène M, Pernot C, Cherrier F. Diagnostic value of the isoproterenol test in effort tachycardia. Arch Mal Coeur Vaiss. 1986;79(3):302–13.PubMedGoogle Scholar
  15. 15.
    Brugada P, Facchini M, Wellens HJJ. Effects of isoproterenol and amiodarone and the role of excercise in initiation of circus movement tachycardia in the accessory atrio-ventricular pathway. Am J Cardiol. 1986;57:146–9.CrossRefGoogle Scholar
  16. 16.
    Niazi I, Nacarelli G, Dougherty A, Rinkenberger R, Tchou P, Akhtar M. Treatment of atrioventricular node reentrant tachycardia with encainide: reversal of drug with isoproterenol. J Am Coll Cardiol. 1989;13:904–10.CrossRefGoogle Scholar
  17. 17.
    Niazi I, Naccarelli G, Dougherty A, Rinkenberger R, Tchou P, Akhtar M. Treatment of AV nodal reentrant tachycardia with encainide: reversal of drug effect on the AV node with isoproterenol. J Am Coll Cardiol. 1989;13:904–10.CrossRefGoogle Scholar
  18. 18.
    Akhtar M, Niazi I, Naccarelli G, Tchou P, Rinkenberger R, Dougherty AH, et al. Role of adrenergic stimulation by isoproterenol in the reversal of effects of encainide in supraventricular tachycardia. Am J Cardiol. 1988;62:45L–9L.CrossRefGoogle Scholar
  19. 19.
    Naccarelli G, Berns E, Dougherty A, Jenkins M, Rinkenberger R. Isoproterenol reversal of encainide effect in the Wolf-Parkinson-White syndrome. PACE. 1987;10:95–100.Google Scholar
  20. 20.
    Manolis AS, Estes NAM. Reversal of electrophysiology effects of flecainide on accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1989;64:194–8.CrossRefGoogle Scholar
  21. 21.
    Brembilla-Perot B, Admant P, Le Helloco A, Pernot C. Loss of efficacy of flecainide in the Wolff Pakinson-White syndrome after isoproterenol administration. Eur Heart J. 1985;6:1074–8.CrossRefGoogle Scholar
  22. 22.
    Helmy I, Scheinman MM, Sharkey H, Herre JM, Griffin JC. Isoproterenol reversal of flecainide effects in patients with accessory pathways. Circulation. 1987;76(suppl IV):IV–69.Google Scholar
  23. 23.
    Wu D, Wyndham C, Amat-Y-Leon F, Denes P, Dhingra RC, Rosen K. The effects of ouabain on induction of atrio-ventricular nodal reentrant paroxysmal tachycardia. Circulation. 1978;57:1171–9.CrossRefGoogle Scholar
  24. 24.
    Bauernfeind RA, Wyndham CR, Dhingra RC, et al. Serial electrophysiologic testing of multiple drugs in patients with atrioventricular nodal reentrant paroxysmal tachycardia. Circulation. 1980;62:1341–9.CrossRefGoogle Scholar
  25. 25.
    Wellens HJ, Duren DR, Liem KL, Lie KI. Effect of digitalis in patients with paroxysmal atrial ventricular nodal tachycardia. Circulation. 1975;52:77–88.Google Scholar
  26. 26.
    Goy JJ, Fromer M, Schlaepfer J, Kappenberger L. Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1991;68:681–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sorin Pripon
    • 1
  1. 1.Cardiologie et Soins Intensifs, Centre Hospitalier de BigorreTarbesFrance

Personalised recommendations